June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Publication|Articles|December 17, 2025
- Ophthalmology Times: November/December 2025
- Volume 50
- Issue 6
Spotlight on women's health: Understanding thyroid eye disease
Author(s)Lynda Charters
Fact checked by: Lisa M. Nijm, MD, JD
Advertisement
Advertisement
Thyroid eye disease (TED), also known as Graves ophthalmopathy or Graves eye disease, is an autoimmune condition in which the immune system targets tissues related to the thyroid.1 This leads to inflammation and swelling, as well as increased growth of muscle and fat behind the eyes.1
Related to this article
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Advertisement
Advertisement